Carlos

Year in Review – 2011

Post author:Carlos
Post published:December 13, 2011
Post category:Uncategorized
Post comments:1 Comment

As 2011 draws to a close, here are a few thoughts on 2011 and 2012: Uncertainty - If there is one word that captures the mood of the year, it…

Drug Delivery Summit Report

Post author:Carlos
Post published:December 5, 2011
Post category:Biotech Conferences Drug Development
Post comments:0 Comments

Lacerta Bio was privileged to give a short talk at the first (and hopefully annual) Drug Delivery Summit in London late last month. While lightly attended, the two-day conference brought…

Insourcing: A new outsourcing approach?

Post author:Carlos
Post published:November 9, 2011
Post category:Downsizing Drug Development Outsourcing Pharmaceutical
Post comments:0 Comments

Pharmaceutical outsourcing to CROs is certainly nothing new. However, this week we learned that pharmaceutical giant Lilly and AMRI signed an interesting insourcing / outsourcing agreement. In this deal, AMRI…

Reformulating Injectables for Oral Delivery

Post author:Carlos
Post published:November 3, 2011
Post category:Drug Delivery
Post comments:0 Comments

Lacerta Bio was pleased to take part in a terrific overview of technologies for oral delivery of peptides and proteins: The oral delivery of biopharmaceuticals is highly desirable because it…

partnering360: Yet another networking platform?

Post author:Carlos
Post published:November 3, 2011
Post category:Conferences Social Media
Post comments:0 Comments

This week, our good "acquaintances" from EBD Group launched partnering360. What is it? According to EBD: partnering360™ is an online network of professionals in the life science industry, emerging from…

AAPS: Impressions and Observations

Post author:Carlos
Post published:October 27, 2011
Post category:Biotech Conferences Drug Delivery Drug Development Entrepreneurship Pharmaceutical
Post comments:0 Comments

Lacerta Bio spent the week at the AAPS ( American Association of Pharmaceutical Scientists ) annual conference . Over 8,000 pharmaceutical scientists, service providers, and others came to AAPS in…

KPMG and Future Pharma

Post author:Carlos
Post published:October 21, 2011
Post category:Drug Development Emerging Markets Pharmaceutical
Post comments:0 Comments

Call us late to the party, but in August of this year, KPMG published Future Pharma: Five Strategies to Accelerate the Transformation of Pharmaceutical Industry... The entire report is available…

When does due diligence start?

Post author:Carlos
Post published:October 12, 2011
Post category:Due Diligence Pharmaceutical
Post comments:0 Comments

In our view, there are two basic types of biotech business development-related due diligence. The first is external , where the team gathers and analyzes data about a target company…

AAPS Conference

Post author:Carlos
Post published:October 4, 2011
Post category:Conferences Drug Development Pharmaceutical
Post comments:0 Comments

In a few weeks, Lacerta Bio will return to DC to participate in the annual convention and celebrate the 25th anniversary of the American Association of Pharmaceutical Scientists (AAPS). AAPS…

Shiraz or Fuller’s Best?

Post author:Carlos
Post published:September 28, 2011
Post category:Biotech Uncategorized Venture Capital
Post comments:0 Comments

Earlier this month, Keith Powell posed an interesting question: The economies of California and the UK are similar, as are the university networks. Why then, does California boast the most…

Get in touch